Onconic Therapeutics (476060.KQ) will present a new obesity drug candidate at ObesityWeek 2026 in Washington, D.C., following its Jaqbo gastrointestinal treatment and Nesuparib cancer candidate. The company said the candidate was discovered and analyzed using artificial intelligence and will be introduced through an oral presentation at the American Obesity Society Academic Conference in November. Its name and research details will be disclosed sequentially. Jaqbo is a potassium-competitive acid blocker known for rapid efficacy and relief from concerns about nighttime heartburn. Nesuparib is undergoing clinical trials for pancreatic, ovarian and stomach cancers, while earlier pipeline information described broader development that also included endometrial cancer.